Patients with systemic lupus erythematosus with a history of cutaneous lupus erythematosus are more likely to have high ...

Losing British drug giant AstraZeneca from the London Stock Exchange would be a “devastating blow”, Tory former chancellor Norman Lamont has said as he warned the Government against using pharma firms ...

Eolas Therapeutics today announced that it has entered into a new agreement with AstraZeneca to assume full development rights to AZD4041, an investigational therapy targeting the orexin-1 receptor, ...

Cheng was a pioneer in clinical trials for tumour diseases, especially small-cell lung carcinoma A top Chinese oncologist and physician-scientist, Cheng Ying, has died suddenly aged 62, according to ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the ...

London has struggled for several years to attract big-name IPOs amid a dearth of liquidity and a less favourable regulatory ...

CEO Pascal Soriot has not hidden his annoyance at taxes and regulations the pharmaceutical firm have to navigate ...

As the UK market grapples with the repercussions of faltering trade data from China, the FTSE 100 and FTSE 250 indices have experienced declines, reflecting broader global economic concerns. In such a ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ongoing $3.5 billion investment in American innovation.